June 1, 2017 / 12:15 PM / 6 months ago

CORRECTED-BRIEF-DSMB recommends Eleven Bio's pivotal trial testing Vicinium continue as planned

(Corrects headline to clarify that board makes recommendations, not the company.)

June 1 (Reuters) - Eleven Biotherapeutics Inc

* Eleven Biotherapeutics announces Data and Safety Monitoring Board (DSMB) recommendation to continue phase 3 registration trial with vicinium in non-muscle invasive bladder cancer based on review of safety and efficacy data

* Eleven Biotherapeutics Inc says expects to complete patient enrollment in 2H2017 and to report topline 3-month data in 2Q2018

* Says DSMB recommended that trial continue without modification

* Eleven Biotherapeutics Inc - plans to enroll 134 patients for trial, at over 70 centers in United States and Canada Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below